Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures

Aikaterini Thanou, Judith A James, Cristina Arriens, Teresa Aberle, Eliza Chakravarty, Joseph Rawdon, Stavros Stavrakis, Joan T Merrill, Anca Askanase, Aikaterini Thanou, Judith A James, Cristina Arriens, Teresa Aberle, Eliza Chakravarty, Joseph Rawdon, Stavros Stavrakis, Joan T Merrill, Anca Askanase

Abstract

Objective: Existing methods for grading lupus flares or improvement require definition-based thresholds as increments of change. Visual analogue scales (VAS) allow rapid, continuous scaling of disease severity. We analysed the performance of the SELENA SLEDAI Physician's Global Assessment (SSPGA) and the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) as measures of improvement or worsening in SLE.

Methods: We evaluated the agreement between prospectively collected measures of lupus disease activity [SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group Index 2004 (BILAG 2004), Cutaneous Lupus Area and Severity Index (CLASI), SSPGA and LFA-REAL] and response [(SLE Responder Index (SRI)-4 and BILAG-Based Combined Lupus Assessment (BICLA)] in a clinical trial.

Results: Fifty patients (47 females, mean age 45 (±11.6) years) were assessed at 528 consecutive visits (average 10.6 (±4.1) visits/patient). Changes in disease activity compared with baseline were examined in 478 visit pairs. SSPGA and LFA-REAL correlated with each other (r=0.936), and with SLEDAI and BILAG (SSPGA: r=0.742 (SLEDAI), r=0.776 (BILAG); LFA-REAL: r=0.778 (SLEDAI), r=0.813 (BILAG); all p<0.0001). Changes (∆) in SSPGA and LFA-REAL compared with screening correlated with each other (r=0.857) and with changes in SLEDAI and BILAG (∆SSPGA: r=0.678 (∆SLEDAI), r=0.624 (∆BILAG); ∆LFA-REAL: r=0.686 (∆SLEDAI) and 0.700 (∆BILAG); all p<0.0001). Changes in SSPGA and LFA-REAL strongly correlated with SRI-4 and BICLA by receiver operating characteristic analysis (p<0.0001 for all). Additionally, LFA-REAL correlated to individual BILAG organ scores (musculoskeletal: r=0.842, mucocutaneous: r=0.826 (p<0.0001 for both)).

Conclusion: SSPGA and LFA-REAL are reliable surrogates of common SLE trial end points and could be used as continuous or dichotomous response measures. Additionally, LFA-REAL can provide individualised scoring at the symptom or organ level.

Trial registration number: NCT02270957.

Keywords: disease activity; outcomes research; systemic lupus Erythematosus.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
(A, B) Correlations between Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) (mm) and SELENA SLEDAI Physician’s Global Assessment (SSPGA) (mm).
Figure 2
Figure 2
(A, B) Correlations between Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) domains (mm) and British Isles Lupus Assessment Group Index (BILAG) organ scores.

References

    1. Györi N, Giannakou I, Chatzidionysiou K, et al. . Disease activity patterns over time in patients with SLE: analysis of the Hopkins lupus cohort. Lupus Sci Med 2017;4:e000192 10.1136/lupus-2016-000192
    1. Askanase AD, Merrill JT. Measuring disease activity in SLE is an ongoing struggle. Nat Rev Rheumatol 2019;15:194–5. 10.1038/s41584-019-0190-1
    1. Thanou A, Merrill JT. Top 10 things to know about lupus activity measures. Curr Rheumatol Rep 2013;15:334 10.1007/s11926-013-0334-2
    1. Buyon JP, Petri MA, Kim MY, et al. . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953–62. 10.7326/0003-4819-142-12_Part_1-200506210-00004
    1. Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8. 10.1056/NEJMoa051135
    1. Isenberg DA, Rahman A, Allen E, et al. . BILAG 2004. development and initial validation of an updated version of the British Isles lupus assessment group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902–6. 10.1093/rheumatology/keh624
    1. Askanase A, Li X, Pong A, et al. . Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med 2015;2:e000075 10.1136/lupus-2014-000075
    1. Furie RA, Petri MA, Wallace DJ, et al. . Novel evidence-based systemic lupus erythematosus Responder index. Arthritis Rheum 2009;61:1143–51. 10.1002/art.24698
    1. Wallace DJ, Kalunian K, Petri MA, et al. . Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183–90. 10.1136/annrheumdis-2012-202760
    1. Wollaston SJ, Farewell VT, Isenberg DA, et al. . Defining response in systemic lupus erythematosus: a study by the systemic lupus international collaborating clinics group. J Rheumatol 2004;31:2390–4.
    1. Isenberg DA, Allen E, Farewell V, et al. . An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54–9. 10.1136/ard.2010.132068
    1. Wallace DJ, Stohl W, Furie RA, et al. . A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168–78. 10.1002/art.24699
    1. Navarra SV, Guzmán RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31. 10.1016/S0140-6736(10)61354-2
    1. Khamashta M, Merrill JT, Werth VP, et al. . Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909–16. 10.1136/annrheumdis-2015-208562
    1. Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an Anti-Interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376–86. 10.1002/art.39962
    1. Askanase AD, Nguyen SC, Costenbader K, et al. . Comparison of the lupus Foundation of America-Rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical Investigators or real-world clinicians. Arthritis Care Res 2018;70:1058–63. 10.1002/acr.23445
    1. Yee C-S, Farewell V, Isenberg DA, et al. . British Isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007;56:4113–9. 10.1002/art.23130
    1. Klein R, Moghadam-Kia S, LoMonico J, et al. . Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203–8. 10.1001/archdermatol.2010.435
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
    1. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49–51. 10.1177/0961203309346505
    1. Choi C-B, Liang MH, Bae S-C. Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Res Ther 2016;18 10.1186/s13075-015-0906-9
    1. American College of rheumatology AD hoc Committee on systemic lupus erythematosus response C. the American College of rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418–26.
    1. Gladman DD, Urowitz MB, Kagal A, et al. . Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377–9.
    1. Yee C-S, Farewell VT, Isenberg DA, et al. . The use of systemic lupus erythematosus disease activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology 2011;50:982–8. 10.1093/rheumatology/keq376
    1. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53–9.
    1. Askanase AD, Daly RP, Okado M, et al. . Development and content validity of the lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes 2019;17:99 10.1186/s12955-019-1151-8

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera